Holen Sie sich die Stockscreener-App
74.52
0.05%
0.04
Vorhandelsmarkt:
76.48
1.96
+2.63%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights
BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals
BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo
BridgeBio raises $1 billion in preferred equity - The Pharma Letter
BridgeBio secures up to $1B in preferred equity - MSN
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN
BridgeBio secures $1 billion in convertible preferred equity - Investing.com
BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan
Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo
Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com
Sector Update: Healthcare - Moomoo
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline - DirectorsTalk Interviews
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark - marketscreener.com
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin - GuruFocus
BridgeBio Pharma, Inc.(NasdaqGS:BBIO) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - The Manila Times
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia - Quiver Quantitative
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO) - TradingView
BridgeBio shareholders approve board changes and equity plan - The Globe and Mail
BBIO Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma Adopts Third Amended 2021 Stock Option and Incentive Plan Following Shareholder Approval - Minichart
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares - Stock Titan
2CL Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma, Inc. Actuals & Estimates (MUN:2CL) - TradingView
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – GETTEX:2CL - TradingView
Enterprise value to EBITDA forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Price to sales forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Enterprise value to EBIT forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma Insider Sold Shares Worth $2,752,270, According to a Recent SEC Filing - marketscreener.com
Price to earnings forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma director Valantine sells $341,523 in shares By Investing.com - Investing.com Australia
BridgeBio Pharma director Valantine sells $341,523 in shares - Investing.com UK
Understanding the Setup: (BBIO) and Scalable Risk - Stock Traders Daily
Form 4 BridgeBio Pharma Inc For: 24 June By Investing.com - Investing.com Australia
BridgeBio Pharma director Jennifer Cook sells $2.75m in stock. By Investing.com - Investing.com Nigeria
BridgeBio Pharma director Jennifer Cook sells $2.75m in stock. - Investing.com
BridgeBio Pharma (BBIO) director sells stock, exercises options and receives RSUs - Stock Titan
BridgeBio (NASDAQ: BBIO) director receives new RSU and stock option awards - Stock Titan
BridgeBio (BBIO) director Charles Homcy receives RSU and stock option awards - Stock Titan
BridgeBio Pharma (BBIO) director awarded RSUs and stock options - Stock Titan
0.93%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):